Daily News Podcast

Empagliflozin and left ventricular mass


 

Empagliflozin significantly reduced left ventricular mass over the course of 6 months in patients who have type 2 diabetes and with stable coronary artery disease. Also today, symptomatic hyperuricemia may respond to urate-lowering therapy, the risk for cancer in non-alcoholic fatty liver disease is 91% higher than the general population, the link between antibiotic use and obesity is insignificant at age 10.

Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Recommended Reading

Biomarkers and concussions
MDedge Infectious Disease
Samuel Shem: Part II
MDedge Infectious Disease
Trump rule and ACA contraception
MDedge Infectious Disease
How to slash colorectal surgery infection rates
MDedge Infectious Disease
Heart failure and sacubiril/valsartan
MDedge Infectious Disease
Vitamin D, fish out, and primary prevention
MDedge Infectious Disease
USPSTF: screen for ‘unhealthy’ alcohol use
MDedge Infectious Disease
Obesity curbs decades of CVD progress
MDedge Infectious Disease
Physical fitness guidelines from HHS
MDedge Infectious Disease
Novel formulation for childhood ADHD
MDedge Infectious Disease